Physician profile
Lance B Steinberg
NPI 1487780532
$5,784.21
in general payments reported to CMS, 2019-2025
24 companies · $997 in 2025
The $997 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $845 · 2021: $861 · 2022: $608 · 2023: $885 · 2024: $748 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613 · Education: $16.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,613.37 |
| Education | $16.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $1,219.36 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Abbvie INC. | $841.09 | 2021-2025 | Vraylar |
| Allergan, INC. | $450.45 | 2019-2020 | |
| Bausch Health US, LLC | $420.22 | 2019-2025 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $396.23 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $371.67 | 2019-2024 | Trintellix |
| Corium, LLC | $274.60 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $232.70 | 2019-2023 | Hetlioz |
| Neos Therapeutics, LP | $218.83 | 2019-2025 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $185.99 | 2019-2022 | |
| Axsome Therapeutics, INC. | $185.97 | 2023-2025 | Sunosi, Auvelity |
| Ironshore Pharmaceuticals INC. | $166.57 | 2019-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $151.30 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $138.62 | 2021-2024 | Caplyta |
| Eisai INC. | $101.45 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $94.07 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $84.39 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $80.88 | 2019-2022 | |
| Noven Therapeutics, LLC | $47.38 | 2024-2025 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $29.07 | 2019 | |
| Adlon Therapeutics L.P. | $28.20 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $25.65 | 2025 | Rexulti |
| Owp Pharmaceuticals, INC. | $21.10 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.42 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Steinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.